Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

FDA perspectives on pharmacogenetic testing.

Courtney C Harper1, Reena Philip, Max Robinowitz

  • 1Center for Devices & Radiological Health, Office of In Vitro Diagnostic Device Evaluation & Safety, US Food & Drug Administration, HFZ-440, 2098 Gaither Rd, Rockville, MD 20850, USA. courtney.harper@fda.hhs.gov

Expert Review of Molecular Diagnostics
|September 10, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Machine learning reveals distinct T-cell receptor clusters in plasma cell dyscrasias compared to healthy controls.

PloS one·2025
Same author

The BCR-SEQC initiative.

Nature immunology·2025
Same author

COVID-19 booster dose vaccination of healthcare workers in Qatar: A web-based cross-sectional survey.

Public health challenges·2025
Same author

Plasma ctDNA as a Treatment Response Biomarker in Metastatic Cancers: Evaluation by the RECIST Working Group.

Clinical cancer research : an official journal of the American Association for Cancer Research·2024
Same author

Empowering effective biomarker-driven precision oncology: A call to action.

European journal of cancer (Oxford, England : 1990)·2024
Same author

US Food and Drug Administration Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2024
Same journal

Bacterial respiratory infections: advances in diagnostic strategies.

Expert review of molecular diagnostics·2026
Same journal

Artificial intelligence in molecular diagnostics for pandemic preparedness.

Expert review of molecular diagnostics·2026
Same journal

Navigating PD-L1 testing in immuno-oncology: analytical robustness, clinical validation, and the role of the VENTANA SP263 assay.

Expert review of molecular diagnostics·2026
Same journal

Extracellular vesicles as diagnostic and prognostic biomarkers in non-small cell lung cancer.

Expert review of molecular diagnostics·2026
Same journal

Explainable epigenetic aging clocks: an overview of existing AI models and approaches.

Expert review of molecular diagnostics·2026
Same journal

Neuro-axonal injury biomarker serum neurofilament light chain is associated with osteoarthritis: a dual-cohort study from NHANES and UK Biobank.

Expert review of molecular diagnostics·2026
See all related articles

Pharmacogenetic testing shows promise for improving patient care and drug development. This article discusses developing in vitro diagnostic devices for pharmacogenetics, focusing on validation challenges.

Area of Science:

  • Pharmacology
  • Genetics
  • Medical Device Development

Background:

  • Pharmacogenetic testing is gaining interest for personalized medicine and optimizing drug development.
  • The US Food and Drug Administration (FDA) recognizes the importance of pharmacogenetics in public health.
  • In vitro diagnostic (IVD) devices are crucial for implementing pharmacogenetic testing.

Purpose of the Study:

  • To outline the FDA's perspective on developing IVDs for pharmacogenetics.
  • To discuss general points and potential issues in the analytical and clinical validation of these devices.

Main Methods:

  • This article presents expert opinion and discussion from the FDA's Office of In vitro Diagnostic Device Evaluation and Safety.
  • It focuses on conceptual and regulatory considerations for pharmacogenetic IVD development.

Related Experiment Videos

Main Results:

  • Key challenges in developing pharmacogenetic IVDs include ensuring analytical and clinical validity.
  • Regulatory considerations are essential for the safe and effective implementation of these tests.

Conclusions:

  • Standardized validation approaches are needed for pharmacogenetic IVDs.
  • Collaboration between developers and regulatory bodies is vital for advancing pharmacogenetic testing.